**[283] IMMUNE ONCOLOGY PHARMACEUTICALS, INC.- A NEW IMMUNO-ONCOLOGY COMPANY**

**Mark Levitt1, Miri Ben-Ami1, 1 Immune Pharmaceuticals, Inc.**

* **Investment Rational**   
  Immune Oncology Pharmaceuticals is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. Its lead clinical-stage product is Ceplene, a first-in-class monocyte-macrophage “checkpoint inhibitor” approved in Europe for AML. The company’s technology platforms includes antibody-targeted nanoparticles and a novel bispecific antibody platform. IOP has a highly skilled and expert team with experience in oncology drug development from large and emerging pharma
* **Business Strategy**   
  IOP’s near term strategy is to expand the approval of Ceplene to the US. IOP is seeking a partner for the second phase 3 study and for commercialization of Ceplene in the US. The company’s proprietary platforms are being developed in scientific collaboration with Prof. Simon Benita and other scientists, to create novel targeted optimized immuno-oncology therapeutics for the longer term.
* **Core Technology**   
  In addition to Ceplene and IL-2 immunotherapy, IOP’s core technologies consist of a targeted nanoparticle platform (NanoMabs™) allowing tumor directed delivery of both internal and external payloads. IOP’s bi-specific antibody program generates unique new molecules based on novel targets discovered by its research teams, providing multiple opportunities to exploit the evolving field of combination immune inhibition.
* **Product Profile/Pipeline**   
  Ceplene will be tested in a registrational trial following agreement on the design of such a study with the FDA in 2016. Research and development of products from the NanoMabs™ and bi-specific antibodies programs has begun in collaboration with several academic laboratories in Israel and France.
* **What's Next?**   
  IOP has recently been established as a subsidiary of Immune Pharmaceuticals Inc in order to secure financial investment focusing on the immune-oncology program leading to the ability to accelerate development towards value producing milestones. IOP is prioritizing development of Ceplene in the US, as well as testing of new molecules from the NanoMabs™ and bi-specific antibodies platforms.